Lopinavir/ritonavir monotherapy as second-line antiretroviral treatment in resource-limited settings: Week 104 analysis of AIDS clinical trials group (ACTG) A5230

by Kumarasamy N., Aga E., Ribaudo H., Wallis C., Katzenstein D., Stevens W., Norton M., Klingman K., Hosseinipour M., Crump J., Supparatpinyo K., Badal-Faesen S., Bartlett J.
Published 2015

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

by Bartlett J., Ribaudo H., Wallis C., Aga E., Katzenstein D., Stevens W., Norton M., Klingman K., Hosseinipour M., Crump J., Supparatpinyo K., Badal-Faesen S., Kallungal B., Kumarasamy N.
Published 2017

Prevention of HIV-1 infection with early antiretroviral therapy

by Cohen M., Chen Y., McCauley M., Gamble T., Hosseinipour M., Kumarasamy N., Hakim J., Kumwenda J., Grinsztejn B., Pilotto J., Godbole S., Mehendale S., Chariyalertsak S., Santos B., Mayer K., Hoffman I., Eshleman S., Piwowar-Manning E., Wang L., Makhema J., Mills L., De Bruyn G., Sanne I., Eron J., Gallant J., Havlir D., Swindells S., Ribaudo H., Elharrar V., Burns D., Taha T., Nielsen-Saines K., Celentano D., Essex M., Fleming T.
Published 2017